Trial Profile
A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination With 5-Azacytidine (5AC, NSC 102816) in Elderly Patients With Acute Myeloid Leukemia (AML)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Entinostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 07 Feb 2024 Planned End Date changed from 1 Dec 2023 to 30 Sep 2024.
- 07 Feb 2024 Planned primary completion date changed from 1 Sep 2023 to 31 Mar 2024.
- 08 May 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.